Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
AAV gene therapy platform and clinical pipeline for genetic disease
AskBio UK Ltd is the European headquarters of AskBio Inc., a fully integrated AAV gene therapy company and Bayer AG subsidiary. Operating from Roslin Innovation Centre, the Edinburgh site develops the company's synthetic promoter technology, data-driven gene expression control sequences that complement AskBio's Pro10…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
Peptide immunotherapies for the treatment of food allergy
Aravax is a clinical-stage biotechnology company developing next-generation specific immunotherapies for food allergy. Its lead candidate, PVX108, is a synthetic peptide-based therapy designed to desensitise peanut-allergic patients by targeting the T cells that drive allergic responses, without triggering acute…
Clinical-stage oncology company advancing in-licensed cancer drug assets
Ellipses Pharma is a clinical-stage oncology drug development company that in-licenses cancer drug assets from academia and industry, advances them through clinical trials using a continuous funding model, and out-licenses at value-inflection points. Its pipeline spans small molecule kinase inhibitors, selective…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
3D immune-microtumour platform for cancer treatment selection
Pear Bio is a biotechnology company that tests cancer treatment efficacy directly on patient-derived tumour samples using three-dimensional immune-microtumour cultures and computer vision analysis. By culturing tumour biopsies with matched patient immune cells and imaging drug effects over time, the platform generates…
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune system by reintroducing disease-specific antigenic epitopes, suppressing the autoaggressive T cell responses that underlie conditions such…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City Place in London, the UK operation employs approximately 1,300 people and focuses on commercialisation, medical affairs, regulatory…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments for neurodegenerative disorders. Its lead candidate, NRG5051, entered Phase 1 clinical trials in January 2026 for ALS and Parkinson's disease.…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain…
AI-powered RNAi drug discovery company developing hepatic medicines
Tangram Therapeutics is a biotechnology company combining artificial intelligence and RNA interference to discover and develop novel medicines. Its proprietary chemistry platform silences disease-driving genes in hepatocytes, and its AI platform drives target identification and siRNA design. The pipeline includes…
Dual-pathway AAV gene therapies for retinal degeneration
Ikarovec is a biotechnology company developing dual-pathway adeno-associated virus gene therapies for retinal diseases. Its lead candidate combines complementary mechanisms targeting complement activity, inflammation and retinal cell protection in geographic atrophy. Additional programmes target wet and intermediate…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The company's approach focuses on blocking microglial dysfunction to restore toxin clearance in the brain. Founded by NLRP3 inflammasome expert Matt…
Engineered bacterial immunotherapies for solid tumours
Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies using engineered Salmonella strains. Its platform combines synthetic biology with AI-enabled discovery to create programmable bacterial therapeutics that deliver payloads within the tumour microenvironment. The lead programme…
Next-generation CAR T-cell therapies for solid tumours
ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours. Its proprietary platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies to enhance T-cell persistence and…
Whole genome synthesis platform engineering novel therapeutic biomolecules
Constructive Bio is a Cambridge-based synthetic biology company developing programmable biology platforms for the creation of novel biomolecules. Spun out of the MRC Laboratory of Molecular Biology, the company's technology combines whole genome synthesis and engineered protein translation to produce molecules…
Oncolytic virus immunotherapies engineered to destroy solid tumours
Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers vaccinia virus to encode antibody-like immunotherapy molecules within the viral genome, enabling localised delivery of immune-activating payloads…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…